Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Oneview Healthcare Chess Depository Interests repr 1 (OtherONVVF)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer (PFE)
In a report released yesterday, Justin Smith from Bernstein maintained a Hold rating on Pfizer, with a price target of $30.00. The company's shares closed last Friday at $24.79, close to its 52-week low of $24.48.
According to TipRanks.com, Smith is ranked #3539 out of 9922 analysts.
Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $28.40, which is a 13.7% upside from current levels. In a report issued on July 22, TR | OpenAI – 4o also downgraded the stock to Hold with a $26.00 price target.
In a report released yesterday, Martyn Jacobs from Bell Potter maintained a Buy rating on Oneview Healthcare Chess Depository Interests repr 1, with a price target of A$0.34. The company's shares closed last Friday at $0.16, equals to its 52-week high of $0.16.
According to TipRanks.com, Jacobs is ranked #9692 out of 9922 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oneview Healthcare Chess Depository Interests repr 1 with a $0.23 average price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 minutes ago
- Forbes
Should You Buy Pfizer Stock Ahead of Its Q2 Results?
Pfizer (NYSE:PFE) is set to announce its earnings on Tuesday, August 5, 2025, prior to the market opening. Analyzing Pfizer's stock performance over the previous five years after earnings announcements indicates a trend towards positive movement. In 53% of cases, PFE stock has experienced a positive one-day return following the announcement of results. The median positive return stands at 3.2%, with a peak one-day gain of 6.1%. For event-driven traders, grasping these historical trends can offer a strategic advantage, although the actual outcomes relative to consensus and expectations will be the final deciding factor. Traders can tackle this from two angles: The consensus analyst forecast for the upcoming quarter points to earnings of $0.58 per share on sales of $13.53 billion. This is in comparison to earnings of $0.60 per share on sales of $13.28 billion in the same quarter the previous year. In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the company generated $62 billion in revenue and sustained operational profitability, with $15 billion in operating profits and a net income of $7.9 billion. That being said, if you are looking for upside with reduced volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and produced returns surpassing 91% since its inception. See earnings reaction history of all stocks Pfizer's Historical Odds Of Positive Post-Earnings Return Here are some insights regarding one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns following earnings is presented alongside the statistics in the table below. Correlation Between 1D, 5D and 21D Historical Returns A relatively less risky strategy (though not effective if the correlation is low) involves understanding the correlation between short-term and medium-term returns following earnings, identifying a pair with the highest correlation, and executing the appropriate trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a 'long' position for the following 5 days if the 1D post-earnings return is positive. Below is some correlation data derived from a 5-year and a 3-year (more recent) history. Note that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns. Is There Any Correlation With Peer Earnings? At times, peer performance can affect the stock reaction following earnings. In fact, pricing might start before the earnings announcement. Here is some historical data on the post-earnings performance of Pfizer stock in comparison with the stock performance of peers that reported earnings just before Pfizer. For a fair comparison, peer stock returns also reflect post-earnings one-day (1D) returns. Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), yielding strong returns for investors. Additionally, if you are interested in upside with a smoother experience than an individual stock such as Pfizer, take a look at the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since inception.
Business Insider
2 hours ago
- Business Insider
Student-loan borrowers on Biden's SAVE plan are struggling to plan for higher payments: 'We're all in limbo'
Mary Smith is considering bankruptcy. "I don't have it," Smith said, referring to the extra money she would need to afford the higher student-loan payments she's facing in the coming year. "Everything we've done, we've done ourselves," Smith said. "Nobody handed me anything. I didn't grow up in a rich family. We live paycheck to paycheck, like most of the country." The 50-year-old nurse is enrolled in former President Joe Biden's SAVE plan, an income-driven repayment plan that offers cheaper monthly payments and a shorter timeline to debt relief. The plan is now on its last legs — it has been blocked since July 2024 due to legal challenges, and Trump's spending law eliminated the plan, replacing it with two less generous options that will go into effect next summer. In addition, the Trump administration restarted interest charges on SAVE balances on August 1 after a yearlong pause. This means Smith and the 8 million other borrowers enrolled in SAVE can either switch to a new plan and likely face higher monthly payments or remain on SAVE for now and watch their balances grow. Smith said that she asked her servicer for an estimate on her interest charges, and she was told it would be about $468 a month. "I did vote for Trump," Smith said, "I am a Trump supporter, but there are a couple of things I don't really agree with, and this is one of them." On the SAVE plan, Smith said her payments were around $150. Federal Student Aid's loan simulator predicted that her payments could surge to nearly $1,000 off the SAVE plan, which Smith said she "definitely cannot afford." Business Insider heard from dozens of student-loan borrowers enrolled in SAVE who are concerned about interest charges restarting and eventually having to move to a different repayment plan. Some borrowers are balancing their agreement with Trump that loans should be repaid with the reality of the financial strain that comes with losing SAVE. Linda McMahon, Trump's education secretary, said in a statement announcing the interest charges restart that the administration is focused on "strengthening the student loan portfolio and simplifying repayment to better serve borrowers." "As part of this effort, the Department urges all borrowers in the SAVE Plan to quickly transition to a legally compliant repayment plan — such as the Income-Based Repayment Plan," McMahon said. "Borrowers in SAVE cannot access important loan benefits and cannot make progress toward loan discharge programs authorized by Congress." Smith is hoping she'll be able to cover the interest charges, but she doesn't have a plan for potentially much higher payments down the road. "It's a struggle. I do agree we have to pay them, but it's really hurting us," Smith said. "It's a shame." 'A wait and see game' Justin Krull's goal is to pay off his student-loan balance. He was never trying to find a way out of repayment, and he wants a concrete plan to fit monthly student-loan payments into his budget. The constantly changing student-loan policies make that difficult. "We're not trying to cheat, we're not trying to not pay our bills," Krull, 42, told BI. "We want to take care of our responsibilities. We just want a system in place that we can rely on and be able to financially plan for our futures and endeavors that exist out there." Krull went back to school in his late 20s on the pre-law track with the goal of earning a law degree, but his priorities changed. He got married and had children, and once the pandemic hit, he lost his job as a retail manager and now works in operations at a factory. He said he qualified for $0 monthly payments on the SAVE plan, and he's been unable to get an estimate of his new payment on a different repayment plan. He plans to see how much interest starts building on his balance and determine at that point whether it makes the most sense for him to remain on SAVE and pay off the interest or take action to get on a new plan. Either way, the uncertainty is taking a toll. "At this point, I'm playing a wait-and-see game and making the move that makes the most sense financially once I can determine what those finances are going to be," Krull said. He added that he's worried he'll have to scale back on his retirement and health savings should his payments surge. Alannah is in a similar boat. Working in public health, she said the SAVE plan halved her payments from around $800 a month to just over $400, which allowed her to put more money into savings and put a down payment on a house. The uncertainty with SAVE has been frustrating, she said, because she planned her budget around her lower monthly payments. Additionally, she heeded the administration's advice and submitted an application to switch to an income-based repayment plan earlier this year, but she said the application is still processing, keeping her in limbo. The Department of Education also posted a notice that loan forgiveness through IBR plans is paused to comply with a court order. Alannah said she plans to hold off on making any student-loan payments until she has certainty that the plan she is on will count toward debt relief. She said that if she paid off her loans aggressively, she would run through her savings — and be left with nothing for retirement. 'Everything right now is backlogged' The changes to SAVE come as the Department of Education itself is undergoing a major overhaul. Trump signed an executive order earlier this year to begin dismantling the department, and the Supreme Court recently ruled that the agency can proceed with firing 1,400 workers, about half of its staff. McMahon said following the ruling that it was "a significant win for students and families" and allows the department the " authority to make decisions about staffing levels, administrative organization, and day-to-day operations." Still, it leaves the department with fewer resources to manage major tasks, including creating a new repayment system and processing millions of borrowers' applications. It has Holly Atkinson, a 57-year-old nurse who voted for Trump, concerned. "It's such a hot mess over there," Atkinson told BI. "Everything right now is backlogged as it is, and if they lay off these people at the Department of Education, it's going to make the situation worse." Atkinson said she was enjoying low monthly payments on the SAVE plan before it was blocked. With her repayment future up in the air, she's now unsure if she'll ever be able to retire with student loans hanging over her head, while also managing a separate private student-loan balance and mortgage payments. "I just feel like it's a weight on my shoulder that's never going to get lifted," she said. "And I see people my age planning to retire and go on vacations and travel, and I don't see any of that happening for me." The department said it would be communicating with SAVE borrowers over the next few months regarding their options to switch to a new repayment plan. Atkinson wishes there was more clarity upfront. "I don't regret voting for him, but what I'm seeing right now makes me very uncomfortable," Atkinson said. "We're all in limbo right now, and I don't like being in limbo."
Yahoo
8 hours ago
- Yahoo
Trump threatens drug giants with crackdown over prices
Donald Trump has threatened to use 'every tool in our arsenal' to crack down on pharmaceutical giants if they fail to cut drug prices for Americans within 60 days. The president wrote to executives at 17 companies on Thursday, demanding they match their US prices for prescription drugs with the lowest price offered in other developed nations. Current prices were an 'unacceptable burden' on US families, Trump said, claiming they could be up to three times higher than in other countries. After returning to the White House earlier this year and pledging to bring down drug prices, the president claimed that 'most proposals' from the pharmaceutical industry amounted to 'more of the same', accusing firms of seeking to shift blame and requesting policies that would pave the way for handouts worths billions of dollars for the sector. 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients,' Trump wrote. 'But if you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices. 'Americans are demanding lower drug prices, and they need them today.' The bosses of Pfizer, AstraZeneca and GSK were among those who received the letters. GSK did not respond to requests for comment. AstraZeneca declined to comment. Pfizer said: 'Pfizer is working closely with the Trump administration and Congress on solutions that will increase access and affordability for American patients and enhance the power of the biopharmaceutical innovation ecosystem in the United States. Our discussions have been productive.' Shares in Pfizer slipped 2%, AstraZeneca fell 3.8% and GSK dropped 3.9% during afternoon trading in New York. At the heart of of Trump's proposal is a status known as 'Most Favored Nation', through which he wants to bind the cost of medications sold in the US to the lowest prices paid elsewhere. The White House is demanding that pharmaceutical companies extend this to drugs used by older people through the government-backed Medicaid health program, as well as new drugs.
